Press release summary
ST. LOUIS โ C2N Diagnostics said Nov. 17 that it has launched a research-use plasma assay designed to quantify six amyloid-beta peptide variants from a single blood sample using high-resolution liquid chromatography-tandem mass spectrometry.
The C2N-Aฮฒ-MAA (6x) measures Aฮฒ37, Aฮฒ38, Aฮฒ39, Aฮฒ40, Aฮฒ42 and Aฮฒ43 with one sample-preparation workflow. C2N said the assay is intended for biopharmaceutical studies examining amyloid processing, including trials of gamma-secretase modulators and other investigational treatments. Researchers may use the peptide profile to study pharmacodynamic effects, dose response and possible relationships with amyloid-related imaging abnormalities.
The plasma assay complements an existing six-analyte cerebrospinal-fluid assay. It is available for research use only and is separate from C2Nโs clinically available Precivity tests.
Why it matters: Measuring several amyloid-beta forms together may give clinical-trial laboratories a more detailed view of how an investigational therapy changes peptide processing than a single ratio or analyte can provide. A shared preparation and LC-MS/MS workflow could also conserve limited plasma and support longitudinal sampling. Laboratories should evaluate calibration, traceability, matrix effects, precision and study-specific interpretation before incorporating the assay into regulated research.








Leave a Reply